(Q37329709)

19 August 2017

1 reference

title

Potential novel pharmacological therapies for myocardial remodelling (English)

1 reference

19 August 2017

1 reference

1

Ulf Landmesser

1 reference

19 August 2017

Kai C Wollert

2

1 reference

19 August 2017

Helmut Drexler

series ordinal

3

1 reference

19 August 2017

publication date

19 November 2008

1 reference

19 August 2017

published in

Cardiovascular Research

1 reference

19 August 2017

volume

81

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

519-527

1 reference

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Mechanisms and models in heart failure: the biomechanical model and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Targeted anticytokine therapy and the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Aldosterone in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Chronic heart failure: an overview of conventional treatment versus novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Role of oxidative stress in cardiac hypertrophy and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Matrix metalloproteinases: regulation and dysregulation in the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Bioenergetic and Functional Consequences of Bone Marrow-Derived Multipotent Progenitor Cell Transplantation in Hearts With Postinfarction Left Ventricular Remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN317

21 January 2018

Identifiers

DOI

10.1093/CVR/CVN317

1 reference

19 August 2017

1 reference